

Approved



Guyana

Country Operational Plan

FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Total
	GAP	GHP-State	GHP-USAID	
DOD		344,369		344,369
HHS/CDC	575,000	2,617,046		3,192,046
PC		127,751		127,751
State		72,269		72,269
USAID		3,446,719	0	3,446,719
Total	575,000	6,608,154	0	7,183,154

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	State/WHA	DOD	HHS/CDC	PC	USAID	AllOther		
CIRC			1,000			20,920		0	21,920
HBHC			20,860	101,660		116,683		0	239,203
HKID						89,266		0	89,266
HLAB			35,000	235,799				0	270,799
HMBL				12,160					12,160
HMIN			13,500					0	13,500
HTXD						500,000		0	500,000
HTXS				511,780		52,299		0	564,079
HVAB			0					0	0
HVCT			30,816	42,160		351,113		0	424,089
HVMS	40,581		80,193	1,208,710	68,463	519,764		0	1,917,711
HVOP		0	40,000	240,319	29,644	301,523		0	611,486
HVSI	31,688	0	40,000	279,540	29,644	438,103		0	818,975
HVTB			38,000	110,799				0	148,799
MTCT				83,240		41,839		0	125,079
OHSS			45,000	272,559		931,531		0	1,249,090

Approved



PDCS				23,620		41,839		0	65,459
PDTX				69,700		41,839		0	111,539
	72,269	0	344,369	3,192,046	127,751	3,446,719	0	0	7,183,154



Budgetary Requirements Worksheet

Redacted

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	174,744	0
HKID	89,266	0
HVTB	88,000	0
PDCS	14,500	0
Total Technical Area Planned Funding:	366,510	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	210,000	0
HVSI	753,847	0
OHSS	1,112,392	0
Total Technical Area Planned Funding:	2,076,239	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	1,000	0
HMIN	13,500	0
HVAB	0	0
HVCT	359,630	0

Approved



HVOP	566,247	0
MTCT	65,000	0
Total Technical Area Planned Funding:	1,005,377	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	500,000	0
HTXS	475,300	0
PDTX	54,500	0
Total Technical Area Planned Funding:	1,029,800	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	147	84
	By program area/support type: HTC Direct Service Delivery (DSD)	141	78
	By program area/support type: HTC Technical Assistance-only (TA)	0	0
	By program area/support type: Treatment Direct Service Delivery (DSD)	3	3
	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
	By program area/support type: Care and Support Direct Service Delivery (DSD)	3	3
	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	3	3
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0



	By program area/support type: PMTCT Direct Service Delivery (DSD)	129	66
	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
	By program area/support type: TB/HIV Direct Service Delivery (DSD)	3	3
	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0
	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	11	11
	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	7	7
	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
	By program area/support	7	7



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	0	0
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	141	78
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0
	By program area/support type: Lab Direct Service Delivery (DSD)	15	14
	By program area/support type: Lab Technical Assistance-only (TA)	0	1
PMTCT_SITE	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	n/a	
	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		3
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		3
	By site support type: Direct Service Delivery (DSD):		



	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	Sum of Numerator Support Type disaggregates		
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		
	Sum of Denominator Support Type disaggregates		
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	62 %	
	Number of pregnant women	9,068	4,584



	with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients	14,680	14,100
	By: Known positives at entry		
	By: Number of new positives identified		
	Sum of Positives Status disaggregates		
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		
	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (NGI)	62 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,068	
	Number of new ANC and L&D clients	14,680	
	By: Known positives at entry		
	By: Number of new positives identified		
	Sum of Positives Status disaggregates		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	16 %	



	mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)		
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	44	46
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	267	154
	Life-long ART (including Option B+)	36	38
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	8	9
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	28	29
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	8	8
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0



	Sum of Regimen Type disaggregates	44	46
	Sum of New and Current disaggregates	36	38
PMTCT_ARV_NGI	PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI)	16 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	44	
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	267	
	Life-long ART (including Option B+)	36	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	8	
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	28	
	Maternal triple ARV prophylaxis (provided with	8	



	the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
	Single-dose nevirapine (with or without tail)	0	
	Sum of Regimen disaggregates	44	
	Sum of New and Current disaggregates	36	
BS_COLL	Number of whole blood collections each year by the NBTS network	10,260	10,260
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	10,260	10,260
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention	3,300	3,650



	intervention including the minimum components during the reporting period.		
	Total number of people in the target population		
	Age/sex: 10-14 Male	0	0
	Age/sex: 15-19 Male	500	400
	Age/sex: 20-24 Male	690	950
	Age/sex: 25-49 Male	1,030	1,130
	Age/sex: 50+ Male	215	236
	Age/sex: 10-14 Female	0	0
	Age/sex: 15-19 Female	200	170
	Age/sex: 20-24 Female	260	320
	Age/sex: 25-49 Female	310	340
	Age/sex: 50+ Female	95	104
	Sum of Age/Sex disaggregates	3,300	3,650
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,900	2,090
	Total estimated number of key population in the		



	catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,000	1,100
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group	800	880



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	110
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG)		



	(Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,634	15,999
	By Test Result: Negative		
	By Test Result: Positive		
	Sum of Test Result disaggregates		
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex:		



	Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex:		



	Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	52	49
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,081	4,079
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	85	82
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,416	11,789
	Sum of Aggregated Age/Sex <15	137	131
	Sum of Aggregated Age/Sex 15+	17,497	15,868
	Sum of Aggregated Age/Sex disaggregates	17,634	15,999
	Service Delivery Point by		



	Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		



	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by		



	Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by		



	Result: Voluntary Counseling & Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,634	
	By Test Result: Negative		
	By Test Result: Positive		



	Sum of Test Result disaggregates		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex: <15 Male	52	
	Aggregated Age/sex: 15+ Male	4,081	
	Aggregated Age/sex: <15 Female	85	
	Aggregated Age/sex: 15+ Female	13,416	
	Sum of Aggregated Age/Sex <15	137	
	Sum of Aggregated Age/Sex 15+	17,497	
	Sum of Aggregated Age/Sex	17,634	



	disaggregates		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		590
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
Sum of Age disaggregates			
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		800
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		



	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex disaggregates		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,350	2,585
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries - By service, age		



	and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS		



	countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age		



	and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS		



	countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	3,287	
	By Age/Sex: <15 Female	90	
	By Age/Sex: <15 Male	72	
	By Age/Sex: 15+ Female	1,648	
	By Age/Sex: 15+ Male	1,477	
	Sum of Age/Sex disaggregates	3,287	
	By Age: <15	162	
	By Age: 15+	3,125	
	Sum of Age disaggregates	3,287	
	By Sex: Female	1,738	
	By Sex: Male	1,549	
	Sum of Sex disaggregates	3,287	
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	0
	By Age/Sex: <15 Female	0	0
	By Age/Sex: <15 Male	0	0



	By Age/Sex: 15+ Female	0	0
	By Age/Sex: 15+ Male	0	0
	Sum of Age/Sex disaggregates	0	0
	By Age: <15	0	0
	By Age: 15+	0	0
	Sum of Age disaggregates	0	0
	By Sex: Female	0	0
	By Sex: Male	0	0
	Sum of Sex disaggregates	0	0
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	3,287	
	By Age/Sex: <15 Female	90	
	By Age/Sex: <15 Male	72	
	By Age/Sex: 15+ Female	1,648	
	By Age/Sex: 15+ Male	1,477	
	Sum of Age/Sex disaggregates	3,287	
	By Age: <15	162	
	By Age: 15+	3,125	
	Sum of Age disaggregates	3,287	
	By Sex: Female	1,738	
	By Sex: Male	1,549	
	Sum of Sex disaggregates	3,287	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	0	
	By Age/Sex: <15 Female	0	
	By Age/Sex: <15 Male	0	
	By Age/Sex: 15+ Female	0	



	By Age/Sex: 15+ Male	0	
	Sum of Age/Sex disaggregates	0	
	By Age: <15	0	
	By Age: 15+	0	
	Sum of Age disaggregates	0	
	By Sex: Female	0	
	By Sex: Male	0	
	Sum of Sex disaggregates	0	
C2.4.D_DSD	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	100 %	
	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	3,287	
	Number of HIV-positive individuals receiving a minimum of one clinical service	3,287	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		3,977
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		2
	Age/sex: 10-14 Male		1
	Age/sex: 15-19 Male		15



	Age/sex: 20-24 Male		54
	Age/sex: 25-49 Male		540
	Age/sex: 50+ Male		35
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		1
	Age/sex: 5-9 Female		2
	Age/sex: 10-14 Female		2
	Age/sex: 15-19 Female		19
	Age/sex: 20-24 Female		144
	Age/sex: 25-49 Female		725
	Age/sex: 50+ Female		50
	Sun of Age/Sex disaggregates		1,590
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		50
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		1,792
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		47
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		2,088
	Sum of Aggregated Age/Sex disaggregates		3,977
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	



	Age/sex: <1 Male	0	
	Age/sex: 1-4 Male	0	
	Age/sex: 5-9 Male	0	
	Age/sex: 10-14 Male	0	
	Age/sex: 15-19 Male	0	
	Age/sex: 20-24 Male	0	
	Age/sex: 25-49 Male	0	
	Age/sex: 50+ Male	0	
	Age/sex: <1 Female	0	
	Age/sex: 1-4 Female	0	
	Age/sex: 5-9 Female	0	
	Age/sex: 10-14 Female	0	
	Age/sex: 15-19 Female	0	
	Age/sex: 20-24 Female	0	
	Age/sex: 25-49 Female	0	
	Age/sex: 50+ Female	0	
	Sum of Age/Sex disaggregates	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
	Sum of Aggregated Age/Sex disaggregates	0	
CARE_NEW_DSD	Number of HIV-infected		307



	adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		2
	Age/sex: 10-14 Male		1
	Age/sex: 15-19 Male		5
	Age/sex: 20-24 Male		7
	Age/sex: 25-49 Male		30
	Age/sex: 50+ Male		10
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		0
	Age/sex: 5-9 Female		2
	Age/sex: 10-14 Female		2
	Age/sex: 15-19 Female		7
	Age/sex: 20-24 Female		14
	Age/sex: 25-49 Female		40
	Age/sex: 50+ Female		10
	Sum of Age/sex disaggregates		130
	Aggregated Age/sex: <15 Male		8
	Aggregated Age/sex: 15+ Male		149
	Aggregated Age/sex: <15 Female		9
	Aggregated Age/sex: 15+		141



	Female		
	Sum of Aggregated Age/sex disaggregates		307
CARE_SITE	CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	n/a	
	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		3
	Total number of PEPFAR supported sites providing clinical care services		3
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical		3



	assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole		0
	Sum of Numerator Site Support Type disaggregates		3
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services		3
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services		0
	Sum of Denominator Site Support Type disaggregates		3
FN_SITE	FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition	n/a	



	assessments that result in an accurate categorization of malnutrition		
	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		2
	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		3
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
	Sum of Numerator Support Type disaggregates		
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites		



	providing nutrition assessment, counseling and support (NACS) services		
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		
	Sum of Denominator Support Type disaggregates		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		3,977
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		3,977
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		



	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Male		
	Sex: Female		
	Sum of Sex disaggregates		
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	61 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	162	99
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	267	154
	By infants who received a virologic test within 2 months of birth		
	By infants who received their first virologic HIV test between 2 and 12 months of age		



	Sum of Infant Age disaggregates		
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,854	3,074
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-14 Male		37
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		1
	Age/Sex: 5-14 Female		52
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	0	0
	Aggregated Age/Sex: <1 Female	0	1
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	1,281	1,378
Aggregated Age/Sex: 1-14 Female			



	Aggregated Age/Sex: 15+ Female	1,434	1,534
	Sum of Aggregated Age/Sex <15	139	161
	Sum of Aggregated Age/Sex 15+	2,715	2,912
	Sum of Aggregated Age/Sex disaggregates	2,854	3,073
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	2,584	
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/Sex: <1 Male	0	
	Aggregated Age/Sex: <1 Female	0	
	Aggregated Age/Sex: <15 Male	65	
	Aggregated Age/Sex: 15+ Male	1,281	
	Aggregated Age/Sex: <15 Female	74	
	Aggregated Age/Sex: 15+ Female	1,434	
	Sum of Aggregated Age/Sex	2,854	



	disaggregates		
	Sum of Aggregated Age/Sex <15	139	
	Sum of Aggregated Age/Sex 15+	2,715	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	232	316
	By Age/Sex: <1 Male		0
	By Age/Sex: 1-4 Male		0
	By Age/Sex: 5-9 Male		0
	By Age/Sex: 10-14 Male		2
	By Age/Sex: 15-19 Male		8
	By Age/Sex: 20-24 Male		7
	By Age/Sex: 25-49 Male		40
	By Age/Sex: 50+ Male		5
	By Age/Sex: <1 Female		0
	By Age/Sex: 1-4 Female		0
	By Age/Sex: 5-9 Female		0
	By Age/Sex: 10-14 Female		12
	By Age/Sex: 15-19 Female		8
	By Age/Sex: 20-24 Female		12
	By Age/Sex: 25-49 Female		35
	By Age/Sex: 50+ Female		11
	Sum of Age/Sex disaggregates		140
	Aggregated Grouping by Age: <1 Male	0	0
	Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male	115	152	
Aggregated Grouping by	0	0	



	Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	107	141
	Sum of Aggregated Age/Sex disaggregates	232	316
	Pregnancy status	16	17
	Breastfeeding status	0	0
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	85 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	209	209
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	246	245
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are		



	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are		



	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who		



	<p>initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>		
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost</p>		



	to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_SITE	TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	n/a	
	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		3
	Total number of PEPFAR-supported ART sites		3
	By support type: Direct Service Delivery (DSD): Number of		



	PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
	Sum of Numerator Site Support Type disaggregates		
	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites		
	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites		
	Sum of Denominator Site Support Type disaggregates		
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such	2	2



	accreditation		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	15	15
	By clinical laboratories		
	By Point-of-care testing sites		
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	n/a	
	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities		32
	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities		
	By: Individuals trained in a nationally- or internationally-recognized pre-service training program		



	By: Individuals who passed a competency-based training to conduct supply chain activities		
	By: Individuals who passed a competency-based training to perform inventory management		
	By: Individuals who passed a competency-based training to develop distribution plans		
	By: Individuals who passed a competency-based training to perform supportive supervision		
	By: Individuals who passed a competency-based training to perform quantification		
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	n/a	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		73
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		79



	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
QI_SITE	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address clinical HIV program processes or outcomes and have documented process results in the last 6 months	n/a	
	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		3
	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		79
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical		



	service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		
	Sum of Numerator Site Support Type disaggregates		
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC		
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		
	Sum of Denominator Site Support Type disaggregates		

Approved





Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7218	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	1,350,043
7352	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	258,519
7369	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	264,176
10074	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	50,000
13245	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	50,000
13384	Davis Memorial Hospital and Clinic	FBO	U.S. Department of Health and Human	GHP-State	401,000



			Services/Centers for Disease Control and Prevention		
14260	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	59,288
14713	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	94,700
14779	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of Western Hemisphere Affairs	GHP-State	0
17122	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	900,000
17577	TBD	TBD	Redacted	Redacted	Redacted
17581	TBD	TBD	Redacted	Redacted	Redacted
17595	Ministry of Health, Guyana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	689,400



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 17595	Mechanism Name: Ministry of Health, Guyana
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Guyana	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 689,400	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	689,400

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

Key Issues

Child Survival Activities

Mobile Population

TB

Family Planning



Budget Code Information

Mechanism ID: 17595			
Mechanism Name: Ministry of Health, Guyana			
Prime Partner Name: Ministry of Health, Guyana			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	6,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	75,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	217,800	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	20,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	128	66	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	128	65	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	127	64	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	128	65	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1		Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to	6	8	Redacted

	reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	227	114	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	6	8	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6	7	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	1	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	6	8	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	6	8	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	6		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	227		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	6		Redacted



PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	6		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	6		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,968	4,484	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	14,580	14,000	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,968		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	14,580		Redacted
BS_COLL	Number of whole blood collections each year by the NBTS network	10,260	10,260	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,389	10,449	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	25	22	Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,267	1,140	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	28	25	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,069	9,262	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	53	47	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	12,336	10,402	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	12,389	10,449	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,389		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	25		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	1,267		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	28		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	11,069		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	53		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	12,336		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	12,389		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,927		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	36		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	30		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	886		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	975		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,927		Redacted
C2.1.D_DSD	By Age: <15	66		Redacted
C2.1.D_DSD	By Age: 15+	1,861		Redacted
C2.1.D_DSD	Sum of Age disaggregates	1,927		Redacted
C2.1.D_DSD	By Sex: Female	922		Redacted

C2.1.D_DSD	By Sex: Male	1,005		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	1,927		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	1,927		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	36		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	30		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	886		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	975		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,927		Redacted
C2.1.D_NGI	By Age: <15	66		Redacted
C2.1.D_NGI	By Age: 15+	1,861		Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,927		Redacted
C2.1.D_NGI	By Sex: Female	922		Redacted
C2.1.D_NGI	By Sex: Male	1,005		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,927		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	1,927		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,927		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	123	60	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	227	114	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,622	1,702	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	0	Redacted



TX_CURR_DSD	Aggregated Age/Sex: <15 Male	29	34	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	825	862	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	34	38	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	734	768	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	63	72	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,559	1,630	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,622	1,702	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	1,622		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	29		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	825		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	34		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	734		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,622		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	63		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,559		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	160	176	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	4	5	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	84	92	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4	4	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	68	75	Redacted



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	160	176	Redacted
TX_NEW_DSD	Pregnancy status	6	7	Redacted
TX_NEW_DSD	Breastfeeding status	0	0	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	148	137	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	174	160	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1	1	Redacted

Implementing Mechanism Details

Mechanism ID: 17581	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17577	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17122	Mechanism Name: Advancing Partners and Communities Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 900,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	900,000

Sub Partner Name(s)

FHI 360	International Center for Research on Women	
---------	--	--

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	250,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	300,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs



Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17122			
Mechanism Name: Advancing Partners and Communities Project			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	64,384	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	89,266	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	97,411	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	279,522	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	88,814	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	280,603	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	11	11
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	7	7
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	7	7
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	7	7
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	7	7
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	7	7
PP_PREV_DSD	Number of the target population who	2,500	2,750



	completed a standardized HIV prevention intervention including the minimum components during the reporting period.		
PP_PREV_DSD	Age/sex: 10-14 Male	0	0
PP_PREV_DSD	Age/sex: 15-19 Male	100	110
PP_PREV_DSD	Age/sex: 20-24 Male	500	550
PP_PREV_DSD	Age/sex: 25-49 Male	1,000	1,100
PP_PREV_DSD	Age/sex: 50+ Male	210	231
PP_PREV_DSD	Age/sex: 10-14 Female	0	0
PP_PREV_DSD	Age/sex: 15-19 Female	100	110
PP_PREV_DSD	Age/sex: 20-24 Female	200	220
PP_PREV_DSD	Age/sex: 25-49 Female	300	330
PP_PREV_DSD	Age/sex: 50+ Female	90	99
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,500	2,750
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,900	2,090
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,000	1,100
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or	0	0



	small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	800	880
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	110
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,105	4,310
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15	15
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,100	2,150
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40	40
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,950	2,105
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	55	55
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,050	4,255
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,105	4,310
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,105	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	15	



HTC_TST_NGI	Aggregated Age/sex: 15+ Male	2,100	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	40	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	1,950	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	55	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	4,050	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	4,105	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,350	2,585
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	7	7

Implementing Mechanism Details

Mechanism ID: 14779	Mechanism Name: State
Funding Agency: State/WHA	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 2,455	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14779			
Mechanism Name: State			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14713	Mechanism Name: National Alliance of State and Territorial AIDS Directors
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 94,700	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 5,100	

Approved



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	94,700

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14713			
Mechanism Name:	National Alliance of State and Territorial AIDS Directors		
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	94,700	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14260	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 59,288	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	59,288

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	29,644
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Education	29,644

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14260			
Mechanism Name: Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	29,644	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	29,644	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13384	Mechanism Name: Positively United to Support Humanity
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Davis Memorial Hospital and Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 401,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	401,000

Sub Partner Name(s)

St. Joseph's Mercy Hospital		
-----------------------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

TB

Budget Code Information

Mechanism ID: 13384			
Mechanism Name: Positively United to Support Humanity			
Prime Partner Name: Davis Memorial Hospital and Clinic			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	64,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	8,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	6,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	5,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	257,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	34,500	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	2	2	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	2	2	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	38	38	Redacted



	during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	40	40	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	30	30	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2	2	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	28	28	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	8	8	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	38	38	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	30	30	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	38		Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	40		Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	30		Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	2		Redacted

	pregnancy			
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	28		Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	8		Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	38		Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	30		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	100	100	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	100	100	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	100		Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	100		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	440	440	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12	12	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	164	164	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	17	17	Redacted



	PERMISSION ONLY: <15 Female			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	247	247	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	29	29	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	411	411	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	440	440	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	440		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	12		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	164		Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	17		Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	247		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	29		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	411		Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	440		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,360		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	54		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	42		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	762		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	502		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	1,360		Redacted
C2.1.D_DSD	By Age: <15	96		Redacted
C2.1.D_DSD	By Age: 15+	1,264		Redacted
C2.1.D_DSD	Sum of Age disaggregates	1,360		Redacted
C2.1.D_DSD	By Sex: Female	816		Redacted
C2.1.D_DSD	By Sex: Male	544		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	1,360		Redacted
C2.1.D_NGI	Number of HIV-positive individuals	1,360		Redacted

	receiving a minimum of one clinical service			
C2.1.D_NGI	By Age/Sex: <15 Female	54		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	42		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	762		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	502		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	1,360		Redacted
C2.1.D_NGI	By Age: <15	96		Redacted
C2.1.D_NGI	By Age: 15+	1,264		Redacted
C2.1.D_NGI	Sum of Age disaggregates	1,360		Redacted
C2.1.D_NGI	By Sex: Female	816		Redacted
C2.1.D_NGI	By Sex: Male	544		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	1,360		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	1,360		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	1,360		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	39	39	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	40	40	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,232	1,372	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	36	37	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	456	516	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	40	52	Redacted



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	700	766	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	76	89	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,156	1,282	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,232	1,371	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	1,232		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	0		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	0		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	36		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	456		Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	40		Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	700		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	1,232		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	76		Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	1,156		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	72	140	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1	2	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	31	60	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1	12	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	39	66	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	72	140	Redacted
TX_NEW_DSD	Pregnancy status	10	10	Redacted

TX_NEW_DSD	Breastfeeding status	0	0	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	61	72	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	72	85	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2	4	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	59	68	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2	4	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70	81	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	38	10	Redacted



	ART)			
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38	10	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	2	2	Redacted

Implementing Mechanism Details

Mechanism ID: 13245	Mechanism Name: Capacity-Building Assistance for Global HIV/AIDS Microbiological Laboratory
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 50,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	50,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

TB

Budget Code Information

Mechanism ID:	13245		
Mechanism Name:	Capacity-Building Assistance for Global HIV/AIDS Microbiological		
Prime Partner Name:	Laboratory American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10074	Mechanism Name: Partnership with HHS/CDC to Assist PEPFAR-built Quality Laboratory
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 50,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

Approved



GHP-State	50,000
-----------	--------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10074		
Mechanism Name:	Partnership with HHS/CDC to Assist PEPFAR-built Quality Laboratory		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7369	Mechanism Name: Department of Defense
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 264,176	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	264,176

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

Military Population

End-of-Program Evaluation

Budget Code Information

Mechanism ID: 7369			
Mechanism Name: Department of Defense			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	20,860	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	38,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	35,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	13,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	30,816	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	40,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	5	5
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	4	4



SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	4	4
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	4	4
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	5	5
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	800	900
PP_PREV_DSD	Age/sex: 10-14 Male	0	0
PP_PREV_DSD	Age/sex: 15-19 Male	400	290
PP_PREV_DSD	Age/sex: 20-24 Male	190	400
PP_PREV_DSD	Age/sex: 25-49 Male	30	30
PP_PREV_DSD	Age/sex: 50+ Male	5	5
PP_PREV_DSD	Age/sex: 10-14 Female	0	0
PP_PREV_DSD	Age/sex: 15-19 Female	100	60
PP_PREV_DSD	Age/sex: 20-24 Female	60	100
PP_PREV_DSD	Age/sex: 25-49 Female	10	10
PP_PREV_DSD	Age/sex: 50+ Female	5	5
PP_PREV_DSD	Sum of Age/Sex disaggregates	800	900
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	700	800
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	550	625
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	150	175



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	700	800
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	700	800
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	700	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	0	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	550	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	0	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	150	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	0	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	700	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	700	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	5	5

Implementing Mechanism Details

Mechanism ID: 7352	Mechanism Name: Measure Evaluation Phase 111
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 258,519	Total Mechanism Pipeline: Redacted
---	---

Approved



Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	258,519

Sub Partner Name(s)

John Snow, Inc.		
-----------------	--	--

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 7352			
Mechanism Name: Measure Evaluation Phase 111			
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	258,519	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7218	Mechanism Name: The Partnership for Supply Chain Management
---------------------------	--

Approved



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

Total All Funding Sources: 1,350,043	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,350,043

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	16,322
----------------------------	--------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	7218		
Mechanism Name:	The Partnership for Supply Chain Management		
Prime Partner Name:	Partnership for Supply Chain Management		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	82,173	0

Approved



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	557,870	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	210,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		33,015		Redacted	33,015	0
ICASS		133,000		Redacted	133,000	0
Management Meetings/Professional Development		30,000		Redacted	30,000	0
Non-ICASS Administrative Costs		9,950		Redacted	9,950	0
Staff Program Travel		41,158		Redacted	41,158	0
USG Staff Salaries and Benefits		691,034	0	Redacted	691,034	0
Total	0	938,157	0	0	938,157	0

U.S. Agency for International Development Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	33,015	0
ICASS		GHP-State		Redacted	133,000	0
Management		GHP-State		Redacted	30,000	0



Meetings/Professional Development						
Non-ICASS Administrative Costs		GHP-State		Redacted	9,950	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		Redacted	0	0
ICASS		0		Redacted	0	8,140
Staff Program Travel				Redacted	0	6,000
USG Staff Salaries and Benefits		80,193		Redacted	80,193	5,667
Total	0	80,193	0	0	80,193	19,807

U.S. Department of Defense Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	0	0
ICASS		GHP-State		Redacted	0	8,140

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		120,183		Redacted	120,183	0
Computers/IT Services		204,000		Redacted	204,000	0
ICASS		389,927		Redacted	389,927	0
Management Meetings/Professional Development		49,186		Redacted	49,186	0
Non-ICASS Administrative Costs		53,255		Redacted	53,255	0
Staff Program Travel		1,000		Redacted	1,000	0
USG Staff Salaries and Benefits	575,000	153,595		Redacted	728,595	0
Total	575,000	971,146	0	0	1,546,146	0

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	120,183	0
Computers/IT Services		GHP-State		Redacted	204,000	0
ICASS		GHP-State		Redacted	389,927	0



Management Meetings/Professional Development		GHP-State		Redacted	49,186	0
Non-ICASS Administrative Costs		GHP-State		Redacted	53,255	0

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
ICASS		22,000		Redacted	22,000	0
Management Meetings/Professional Development		5,000		Redacted	5,000	0
Staff Program Travel		6,000		Redacted	6,000	0
USG Staff Salaries and Benefits		39,269		Redacted	39,269	0
Total	0	72,269	0	0	72,269	0

U.S. Department of State Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
ICASS	ICASS	GHP-State		Redacted	22,000	0
Management Meetings/Professional	Training	GHP-State		Redacted	5,000	0



Development						
-------------	--	--	--	--	--	--

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Indirect Costs		0		Redacted	0	0
Institutional Contractors				Redacted	0	0
Non-ICASS Administrative Costs		0		Redacted	0	0
Peace Corps Volunteer Costs		68,463		Redacted	68,463	0
Staff Program Travel				Redacted	0	0
USG Staff Salaries and Benefits		0		Redacted	0	0
Total	0	68,463	0	0	68,463	0

U.S. Peace Corps Other Costs Details

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Indirect Costs		GHP-State	Staff Travel	Redacted	0	0
Non-ICASS Administrative Costs		GHP-State	Printing, Supplies	Redacted	0	0